Carbidopa and Levodopa
Carbidopa and Levodopa is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Carbidopa and Levodopa; Generic name: CARBIDOPA AND LEVODOPA; Drug class: Aromatic Amino Acid Decarboxylation Inhibitor [EPC].
| Brand name | Carbidopa and Levodopa |
|---|---|
| Generic name | CARBIDOPA AND LEVODOPA |
| Drug class | Aromatic Amino Acid Decarboxylation Inhibitor [EPC] |
| Manufacturer | A-S Medication Solutions |
| Used for | INDICATIONS AND USAGE Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa |
| Dosage | DOSAGE AND ADMINISTRATION The optimum daily dosage of carbidopa and levodopa tablets must be determined by careful titration in each patient. Carbidopa and levodopa tablets are available in a 1:4 ratio of carbidopa to levodopa (carbidopa and levodopa tablets 25 mg/100 mg) as well as 1:10 ratio (carbidopa and levodopa tablets 25 mg/250 mg and carbidopa and levodopa tablets 10 mg/100 mg). Tablets of the two ratios may be given separately or combined as needed to provide the optimum dosage. Studies |
| Warnings | WARNINGS When carbidopa and levodopa tablets are to be given to patients who are being treated with levodopa, levodopa must be discontinued at least twelve hours before therapy with carbidopa and levodopa is started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy. The addition of carbidopa with levodopa in the form of carbidopa and levodopa tablets reduces the peripheral effects (nausea, vomiting) du |
| Active ingredient(s) | CARBIDOPA |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08f51366-0a54-48f5-8f10-940745850325 |